Approval · Notice of Compliance 35903 · 2025
UBRELVY: Notice of Compliance 35903
Issued August 26, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35903
- Date
- August 26, 2025
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information / Product Monograph reformatted to the Master Template / Update to package insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| UBRELVY | Not yet assigned | — |
Medicinal ingredients
- UBROGEPANT 50 MG per TAB
- UBROGEPANT 100 MG per TAB